On April 6, 2022, Yuanxin Technology and Elixir Clinical Research announced a formal strategic cooperation agreement between the two companies. According to the agreement, both parties will carry out in-depth cooperation in such fields as real-world studies. Both parties will give full play to their respective strengths to provide multi-dimensional high-value data analysis support for clinical research and decision support for medical institutions and pharmaceutical companies through the integration of pharmaceutical services supply chain capabilities and real-world studies, which will further enrich clinical research tools, improve decision making, accelerate the process of new drug development and results translation, and help the industry achieve high-quality development.

With the continuous integration of clinical research with big data, cloud computing and artificial intelligence, multi-dimensional high-value data analysis and mining has become a “booster” to improve the quality and efficiency of new drug development. Real-world data combines a variety of disciplinary methods and technologies, and integrates multiple data resources to evaluate the effects of drugs in real clinical settings, providing more clinically relevant medical evidence for clinical research, drug development and even public health decisions, and its research results are closer to clinical practice. The ability to collect, summarize, manage, and analyze real-world data has increasingly become an important indicator for measuring the level of corporate strategic planning and long-term development.

Therefore, the first step in learning SAS is to gain systematic knowledge. Specifically, SAS is divided into data and procedures. Which functions are commonly used in the data? What are the general roles of these functions? Which procedures are commonly used? And what are the differences between main usages of many similar procedures? As for the parameters of each function and the specific way to code each proc step, these can be accumulated slowly in future work. Besides, SAS also comes with a SAS help module, which records almost all SAS functions and the usages of some functions. As a programmer, you should form a habit of actively checking SAS help at work, after all, because the knowledge in this module is the most authoritative and comprehensive content available.

April 15, 2022 came the 28th National Cancer Prevention and Treatment Publicity Week. In order to respond to the national call and help new cancer drug development, this strategic cooperation would also focus on exploring the possibility and effectiveness of real-world study cooperation in the field of cancer, aiming at making innovation to boost new cancer drugs development, and injecting new momentum to improve the survival quality of cancer patients in China.

Dai Chao, Assistant President of Yuanxin Technology, said:

“As a medical technology company dedicated to delivering value to patients, Yuanxin Technology takes real-world studies as one of its strategic plans for future deployment. Focusing on the solution capabilities in terms of online and offline integration, in-hospital and out-of-hospital linkage, and medical insurance integration, the group’s Miaoshou Doctor platform, more than 250 hospital-side pharmacies and more than 340 Internet hospitals built and operated by the group’s Yuanxin Medical, jointly constitute our efficient, scientific, and complete supply chain system, which can solve the key issues of matches between patients and data for real-world studies. We hope to fully integrate our strengths in supply chain capabilities and clinical research digitization through our collaboration with Elixir Clinical Research to drive new drug development, launching and evaluation based on more and more valid real-world evidence.”

Dr. Yuji Feng, Associate General Manager and Head of Real-World Studies at Elixir Clinical Research, said:    “Rooted in China, serving the world, as an international technology-enabled full service CRO, Elixir Clinical Research is committed to empowering clinical study and operations with digital technology to provide new impetus to the clinical study. With regard to real-world studies, Elixir Clinical Research has a long-term strategic plan and solid industrial practice experience to carry out high-quality clinical study solutions using digital platforms and tools in post-marketing studies and real-world studies, which helps companies and the medical industry to perform relevant research, promotes the realization of industrial transformation, and improves the quality and efficiency of clinical study. This collaboration will also surely further enhance the research level of Elixir Clinical Research in the field of real-world studies, accelerate the entry of innovative drugs into healthcare system, improve healthcare services, and benefit Chinese people.”

In 2020, the National Medical Products Administration (NMPA) released the first “Guidelines for Real-World Evidence to Support Drug Development and Review (Interim)”, marking a new stage in the drug development and evaluation in China. This strategic collaboration between Yuanxin Technology and Elixir Clinical Research follows the trend of new drug development, establishes a digital bridge for patients, companies and the healthcare industry to connect to real-world studies, and promotes the common innovative development in such dimensions as industry chain, supply chain and value chain. In the future, by relying on its platform resources, medical technology capabilities and supply chain capabilities, Yuanxin Technology will work together with Elixir Clinical Research to carry out multi-level innovation and cooperation, and empower the process of new drug development and launching, so that innovative drugs can benefit more patients faster.

About Elixir Clinical Research

Rooted in China, serving the world. Elixir Clinical Research Co., Ltd. is a professional technology-enabled full service CRO. With the mission of “making good drugs accessible”, it provides pharmaceutical companies with high-quality and effective clinical research solutions to facilitate the launching of new drugs.

Business covers BE, Phase I-IV clinical trials, real-world studies, and eventual registration application and filing. With many years of practical experience in the informatization operation and management of clinical research and continuous development and integration of industrial resources, Elixir Clinical Research has established a unique new type of clinical research model: with informatization operation and management of projects, files, personnel, data, adverse reactions, etc., it has laid a solid foundation for the high-quality development of clinical study projects. Elixir Clinical Research continues to maintain communication among clinical research institutions, third-party partners and regulatory authorities and by connecting all relevant parties involved in clinical studies, it has established an efficient, transparent and collaborative project operation mechanism.

About Yuanxin Technology

Beijing Yuanxin Technology Group Co., Ltd. (“Yuanxin Technology”) is a healthcare company dedicated to delivering value to patients. Established in 2015, the Beijing-based group now employs over 4,000 professionals.

Yuanxin Technology’s business model focuses on patients’ whole medical service cycle. Yuanxin Technology features three pillar services, namely, out-of-hospital comprehensive patient service, supply side empowerment service and innovative healthcare service. All these services are committed to realizing one common goal of building a synergetic healthcare platform that provides comprehensive, personalized and considerate services to patients.

With online and offline channels, Yuanxin integrates hospital and out-of-hospital resources and delivers integrated medical insurance solutions. By breaking the traditional boundary of medical services, pharmaceutical circulation, health insurance, and IT application in healthcare, it establishes a patient-centered digital course management system featuring extensive involvement of hospitals, physicians, pharmaceutical companies and insurers, so as to contribute to the sustainability of the healthcare industry.